Sarah Fritchley

569 total citations
9 papers, 476 citations indexed

About

Sarah Fritchley is a scholar working on Oncology, Immunology and Allergy and Cell Biology. According to data from OpenAlex, Sarah Fritchley has authored 9 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Immunology and Allergy and 5 papers in Cell Biology. Recurrent topics in Sarah Fritchley's work include Cell Adhesion Molecules Research (6 papers), Chemokine receptors and signaling (5 papers) and Proteoglycans and glycosaminoglycans research (5 papers). Sarah Fritchley is often cited by papers focused on Cell Adhesion Molecules Research (6 papers), Chemokine receptors and signaling (5 papers) and Proteoglycans and glycosaminoglycans research (5 papers). Sarah Fritchley collaborates with scholars based in United Kingdom, Netherlands and Switzerland. Sarah Fritchley's co-authors include Simi Ali, John A. Kirby, Amanda E. I. Proudfoot, Paul R. Clapham, Alexandra Trkola, David Marchant, Catherine Zwahlen, Timothy N. C. Wells, Francis Vilbois and Jeffrey P. Shaw and has published in prestigious journals such as Journal of Biological Chemistry, Biochemical Journal and Protein Science.

In The Last Decade

Sarah Fritchley

9 papers receiving 467 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Fritchley United Kingdom	8	230	217	173	148	117	9	476
Christine Montixi France	7	73 0.3×	428 2.0×	409 2.4×	129 0.9×	59 0.5×	8	791
Cynthia Detre United States	15	71 0.3×	443 2.0×	151 0.9×	51 0.3×	39 0.3×	18	620
Irene Ivhed Sweden	9	91 0.4×	177 0.8×	287 1.7×	70 0.5×	28 0.2×	12	556
Yoshimi Tobita Japan	9	79 0.3×	89 0.4×	266 1.5×	200 1.4×	80 0.7×	11	581
Florian Peters Germany	12	96 0.4×	241 1.1×	142 0.8×	52 0.4×	72 0.6×	20	478
Amélie Bouchard Canada	11	249 1.1×	279 1.3×	262 1.5×	29 0.2×	31 0.3×	13	613
Emil H. Palacios United States	7	224 1.0×	659 3.0×	319 1.8×	44 0.3×	42 0.4×	8	994
Paolo Polzella United Kingdom	10	166 0.7×	587 2.7×	176 1.0×	41 0.3×	31 0.3×	15	787
Silvio Calderara Switzerland	7	63 0.3×	250 1.2×	325 1.9×	85 0.6×	31 0.3×	7	523
Anita Diu France	10	169 0.7×	525 2.4×	446 2.6×	50 0.3×	23 0.2×	16	898

Countries citing papers authored by Sarah Fritchley

Since Specialization

Citations

This map shows the geographic impact of Sarah Fritchley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Fritchley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Fritchley more than expected).

Fields of papers citing papers by Sarah Fritchley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Fritchley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Fritchley. The network helps show where Sarah Fritchley may publish in the future.

Co-authorship network of co-authors of Sarah Fritchley

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Fritchley. A scholar is included among the top collaborators of Sarah Fritchley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Fritchley. Sarah Fritchley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Bet, Pierre M., Jos W. R. Twisk, Sarah Fritchley, et al.. (2023). Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19. European Journal of Pharmaceutical Sciences. 184. 106418–106418. 3 indexed citations

2.

Vuylsteke, Alain, et al.. (2006). APT070 inhibits complement activation during in vitro cardiopulmonary bypass. European Journal of Cardio-Thoracic Surgery. 30(1). 72–76. 7 indexed citations

3.

Lukacik, Petra, Dirk Eßer, Michael Steward, et al.. (2004). Biological activity, membrane‐targeting modification, and crystallization of soluble human decay accelerating factor expressed inE. coli. Protein Science. 13(9). 2406–2415. 38 indexed citations

4.

Ali, Simi, et al.. (2002). Contribution of the putative heparan sulfate-binding motif BBXB of RANTES to transendothelial migration. Glycobiology. 12(9). 535–543. 34 indexed citations

5.

Proudfoot, Amanda E. I., Sarah Fritchley, Frédéric Borlat, et al.. (2001). The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity. Journal of Biological Chemistry. 276(14). 10620–10626. 211 indexed citations

6.

Ali, Simi, et al.. (2001). Multimerization of monocyte chemoattractant protein-1 is not required for glycosaminoglycan-dependent transendothelial chemotaxis. Biochemical Journal. 358(3). 737–737. 20 indexed citations

7.

Ali, Simi, et al.. (2001). Multimerization of monocyte chemoattractant protein-1 is not required for glycosaminoglycan-dependent transendothelial chemotaxis. Biochemical Journal. 358(3). 737–745. 14 indexed citations

8.

Ali, Simi, et al.. (2000). Examination of the Function of RANTES, MIP-1α, and MIP-1β following Interaction with Heparin-like Glycosaminoglycans. Journal of Biological Chemistry. 275(16). 11721–11727. 112 indexed citations

9.

Fritchley, Sarah, John A. Kirby, & Simi Ali. (2000). The antagonism of interferon-gamma (IFN-γ) by heparin: examination of the blockade of class II MHC antigen and heat shock protein-70 expression. Clinical & Experimental Immunology. 120(2). 247–252. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact